Strong Q1 2015 Leads To Increasing 12 Month NYSE Price Targets, For Merck

The strong quarter Kenilworth posted last week is causing the bankers to raise their price targets, bit by bit, here. This is CSFB, via Benzinga:

. . . .Neutral, but up to $62 from $60 [12 month price target]. Credit Suisse rated both of those stocks [Lilly and Merck] at Neutral. . . .

I do think Merck is starting to hit its stride, finally -- even if CSFB prefers Pfizer at the moment, in the space (and it does). Soft, quiet and cool rain falling. . . onward.